Semaglutide (brand names: Ozempic, Rybelsus, and Wegovy) is an antidiabetic and anti-obesity drug. Its developer, Novo Nordisk, has three ongoing phase 3 trials run across the world of semaglutide for Alzheimer’s disease:
NCT04777396: 1,840 participants, started in 2021, results expected in 2026,
NCT05891496: 24 participants, started in 2023, results expected in 2025,
NCT04777409: 1,840 participants, started in 2021, results expected in 2026.
Will semaglutide be approved by the Food and Drug Administration (FDA) for Alzheimer's (or any kind of cognitive impairment) before January 1st, 2030?
Approval can be for the treatment (whether symptomatic or disease-modifying) or prevention of the targeted disease.
1,000People are also trading
Update since the description was written: both Phase 3 trials read out and missed. On 24 November 2025 Novo Nordisk reported that EVOKE and EVOKE+ (3,808 people aged 55 to 85 with early Alzheimer's and confirmed amyloid, 104 weeks of oral semaglutide versus placebo) did not show superiority on CDR-SB, the primary cognition-and-function endpoint, even though amyloid-related biomarkers improved; the one-year extensions were discontinued. An approval before 2030 would therefore need a new Phase 3 designed, run and filed inside about three years, with no efficacy signal to build it on. What GLP-1 drugs still have in the aging space is the mortality signal (SELECT: 19% lower all-cause death in overweight adults with heart disease) and a slot in VITAL-H, the ARPA-H-funded healthspan trial in 726 adults aged 60 to 65, which measures function rather than a disease. Whether any drug gets an aging indication at all (mine): /w0lph/will-the-fda-approve-any-drug-for-a
Betting NO at ~5% estimate.
Both EVOKE and EVOKE+ phase 3 trials (3,808 participants) failed all primary and secondary endpoints — no benefit for cognition or function vs placebo at 104 weeks. Novo Nordisk terminated the program entirely in November 2025. Full data presented at AD/PD conference March 2026 confirmed no clinical efficacy.
With the program terminated and no active development pathway, FDA approval before 2030 would require Novo Nordisk to restart from scratch with a new trial design — which they show no indication of doing. The 5% accounts for an extremely unlikely scenario where another company licenses semaglutide for a different Alzheimer-adjacent indication.